Janus Kinase 2

"Janus Kinase 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.

Descriptor ID	D053614
MeSH Number(s)	D08.811.913.696.620.682.725.124.200 D12.776.476.393.200 D12.776.624.664.700.117
Concept/Terms	Janus Kinase 2 Janus Kinase 2 JAK-2 Protein Tyrosine Kinase JAK 2 Protein Tyrosine Kinase JAK2 Protein Tyrosine Kinase

Below are MeSH descriptors whose meaning is more general than "Janus Kinase 2".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
Janus Kinases [D08.811.913.696.620.682.725.124]
Janus Kinase 2 [D08.811.913.696.620.682.725.124.200]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Intracellular Signaling Peptides and Proteins [D12.776.476]
Janus Kinases [D12.776.476.393]
Janus Kinase 2 [D12.776.476.393.200]
Neoplasm Proteins [D12.776.624]
Oncogene Proteins [D12.776.624.664]
Proto-Oncogene Proteins [D12.776.624.664.700]
Janus Kinase 2 [D12.776.624.664.700.117]

Below are MeSH descriptors whose meaning is related to "Janus Kinase 2".

Below are MeSH descriptors whose meaning is more specific than "Janus Kinase 2".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Janus Kinase 2" by people in this website by year, and whether "Janus Kinase 2" was a major or minor topic of these publications.

Bar chart showing 12 publications over 9 distinct years, with a maximum of 2 publications in 2006 and 2012 and 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	0	1	1
2006	0	2	2
2011	0	1	1
2012	1	1	2
2013	0	1	1
2015	1	0	1
2016	1	1	2
2020	0	1	1
2024	0	1	1

Below are the most recent publications written about "Janus Kinase 2" by people in Profiles.

Kohal R, Bisht P, Gupta GD, Verma SK. Targeting JAK2/STAT3 for the treatment of cancer: A review on recent advancements in molecular development using structural analysis and SAR investigations. Bioorg Chem. 2024 02; 143:107095.

View in: PubMed
Kay J, Harigai M, Rancourt J, Dickson C, Melby T, Issa M, de la Torre I, Isaka Y, Cardoso A, Saifan C, Keystone EC, van Vollenhoven RF, Giles JT, Huizinga TW, Kremer JM. Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open. 2020 10; 6(3).

View in: PubMed
Wang JC, Chen C, Kundra A, Kodali S, Pandey A, Wong C, Cheung T, Gotlieb V, Joseph G, Tribie S. Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms. Leuk Res. 2019 04; 79:52-59.

View in: PubMed
Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, Murakami M, Shigemori K, Morrow SN, Van Scoyk A, Cordero NA, Stevenson KE, Puligandla M, Haas B, Lo C, Meyers R, Gao G, Cherniack A, Louissaint A, Nardi V, Thorner AR, Long H, Qiu X, Morgan EA, Dorfman DM, Fiore D, Jang J, Epstein AL, Dogan A, Zhang Y, Horwitz SM, Jacobsen ED, Santiago S, Ren JG, Guerlavais V, Annis DA, Aivado M, Saleh MN, Mehta A, Tsherniak A, Root D, Vazquez F, Hahn WC, Inghirami G, Aster JC, Weinstock DM, Koch R. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018 05 22; 9(1):2024.

View in: PubMed
Chen Y, Shan Y, Lu M, DeSouza N, Guo Z, Hoffman R, Liang A, Li S. Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice. Cancer Res. 2017 01 01; 77(1):164-174.

View in: PubMed
Li G, Hayward IN, Jenkins BR, Rothfuss HM, Young CH, Nevalainen MT, Muth A, Thompson PR, Navratil AM, Cherrington BD. Peptidylarginine Deiminase 3 (PAD3) Is Upregulated by Prolactin Stimulation of CID-9 Cells and Expressed in the Lactating Mouse Mammary Gland. PLoS One. 2016; 11(1):e0147503.

View in: PubMed
Mace TA, Shakya R, Elnaggar O, Wilson K, Komar HM, Yang J, Pitarresi JR, Young GS, Ostrowski MC, Ludwig T, Bekaii-Saab T, Bloomston M, Lesinski GB. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. Oncotarget. 2015 Dec 29; 6(42):44509-22.

View in: PubMed
Chang H, Shih LY, Michelson AD, Dunn P, Frelinger AL, Wang PN, Kuo MC, Lin TL, Wu JH, Tang TC. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study. Acta Haematol. 2013; 130(3):181-7.

View in: PubMed
Mashili F, Chibalin AV, Krook A, Zierath JR. Constitutive STAT3 phosphorylation contributes to skeletal muscle insulin resistance in type 2 diabetes. Diabetes. 2013 Feb; 62(2):457-65.

View in: PubMed
Looyenga BD, Hutchings D, Cherni I, Kingsley C, Weiss GJ, Mackeigan JP. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One. 2012; 7(2):e30820.

View in: PubMed

People

Explore

Similar Concepts

Top Journals